CCSS Achieves Major Price Reduction for Cancer Immunotherapy Drug

In a significant move for public health and patient access, Costa Rica's Social Security Fund (CCSS) has achieved a substantial reduction in the cost of Pembrolizumab, commercially known as Keytruda. This high-cost immunotherapy, a critical treatment for various cancers, will now be available at a nearly 50% lower price following confidential negotiations.

This breakthrough is particularly noteworthy as Keytruda represents the largest annual expenditure for the CCSS among high-cost medications. The drug is also the subject of numerous legal challenges, known as 'amparos,' where patients seek court orders to access treatments not readily covered or approved. The CCSS's success in negotiating this price decrease is a testament to its strategic approach to managing pharmaceutical costs while expanding patient access.

The agreement stipulates that the price reduction is contingent upon extending the use of Pembrolizumab to cover 21 different types of cancer. This expansion promises to benefit a wider range of patients who could benefit from this advanced form of cancer treatment, marking a significant step forward in the country's healthcare system.

Keytruda, a cornerstone of modern cancer treatment, works by harnessing the patient's own immune system to fight cancer cells. Its effectiveness against various malignancies has made it a vital, albeit expensive, therapeutic option. The CCSS's proactive negotiation demonstrates a commitment to making such life-saving treatments more accessible and sustainable within the national healthcare framework.